Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.

Cox MC, Castiello L, Mattei M, Santodonato L, D'Agostino G, Muraro E, Martorelli D, Lapenta C, Di Napoli A, Di Landro F, Cangemi M, Pavan A, Castaldo P, Hohaus S, Donati S, Montefiore E, Berdini C, Carlei D, Monque DM, Ruco L, Prosperi D, Tafuri A, Spadaro F, Sestili P, Spada M, Dolcetti R, Santini SM, Rozera C, Aricò E, Capone I, Belardelli F.

Clin Cancer Res. 2019 Sep 1;25(17):5231-5241. doi: 10.1158/1078-0432.CCR-19-0709. Epub 2019 Jun 6.

PMID:
31171545
2.

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Castiello L, Sestili P, Schiavoni G, Dattilo R, Monque DM, Ciaffoni F, Iezzi M, Lamolinara A, Sistigu A, Moschella F, Pacca AM, Macchia D, Ferrantini M, Zeuner A, Biffoni M, Proietti E, Belardelli F, Aricò E.

Cancer Immunol Res. 2018 Jun;6(6):658-670. doi: 10.1158/2326-6066.CIR-17-0675. Epub 2018 Apr 5.

3.

A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

Torelli GF, Rozera C, Santodonato L, Peragine N, D'agostino G, Montefiore E, Napolitano MR, Monque DM, Carlei D, Mariglia P, Pauselli S, Gozzer M, Bafti MS, Girelli G, Guarini A, Belardelli F, Foà R.

Blood Transfus. 2015 Jul;13(3):464-71. doi: 10.2450/2015.0231-14. Epub 2015 Jan 30.

4.

MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68.

Aricò E, Monque DM, D'Agostino G, Moschella F, Venditti M, Kalinke U, Allen DJ, Stewart JP, Nash AA, Belardelli F, Ferrantini M.

Vaccine. 2011 May 23;29(23):3935-44. doi: 10.1016/j.vaccine.2011.03.092. Epub 2011 Apr 8. Erratum in: Vaccine. 2012 Apr 26;30(20):3145. Stewart, James P [added].

PMID:
21481326
5.

Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.

Santodonato L, D'Agostino G, Nisini R, Mariotti S, Monque DM, Spada M, Lattanzi L, Perrone MP, Andreotti M, Belardelli F, Ferrantini M.

J Immunol. 2003 May 15;170(10):5195-202.

Supplemental Content

Loading ...
Support Center